novocure clinical trials

The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields. About pancreatic cancer: Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the United States. The Clinical Trial Communications Associate will focus on writing and editing communications materials for our clinical trial efforts, including the website, patient/site-facing materials, and indirect channels in order to increase awareness of the … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. … Our research shows that Tumor Treating Fields can have an anti-mitotic effect in 18 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. Pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, at just 8 percent. About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies … Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Novocure ($7 billion, -20% YTD) is an oncology company that offers a novel therapy called Tumor Treating Fields, which uses electric fields to … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of … Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Cancer type: Brain metastases from non-small cell lung cancer (Phase 3 pivotal). Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Please click here to access it. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Seattle Clinical Trial Associate, ROW - WA, 98119. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … The Clinical Trial Communications Associate is responsible for supporting the Clinical Operations department in advancement of the company’s clinical program. The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials… He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. Cancer type: Non-small cell lung cancer (Phase 3 pivotal). “There are few possibilities to treat these patients,” … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. The incidence of liver cancer is approximately 42,000 new cases annually in the U.S., approximately 82,000 new cases annually in Europe, and approximately 42,000 new cases annually in Japan. Novocure has ongoing or completed clinical trials … This information is for medical, and scientific and educational purposes only. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. We expect our colleagues to excel, and in return, we invest in their professional growth and … Headquartered in Jersey, Novocure … Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. Limited by federal law to investigational use only. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from the Optune ® System [About TTFields] together … Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Salaries posted anonymously by Novocure employees. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Hepatocellular carcinoma is the most widespread type of cancer that originates from the liver. We sponsor clinical trials of Tumor Treating Fields in several cancer types. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. Advancing our clinical pipeline in indications with significant unmet need. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. We have revised our Privacy Policy that is in effect as of May 25, 2018. clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … The study posted an overall … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Novocure is the sponsor of clinical trials testing TTFields in several cancers. … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Novocure Vulnerability Disclosure Process. Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … TTFields is currently being tested for other cancers in various clinical trials, presented in this website. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. Novocure Clinical Trial Investigator Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy. Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC. This website intends to use cookies to improve the site and your experience. In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. The study posted an overall survival of 18.2 months in people who received NovoTTF … Professor Yoram Palti founded Novocure in 2000. We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. Novocure is the sponsor of clinical trials testing TTFields in several cancers. NovoCure announced today that it has entered a clinical trial collaboration agreement with Merck.Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC). About hepatocellular cancer: Liver cancer is a leading cause of cancer deaths worldwide and is the seventh leading cause of cancer deaths annually in the U.S. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. annually in Japan. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … By continuing to browse the site you are agreeing to accept our use of cookies. The science of Tumor Treating Fields extends beyond glioblastoma. … This is a full-time, exempt, field-based position that reports to the Clinical Trial … The five-year survival rate with existing standards of care is less than 18%. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Work on increasing awareness of Novocure clinical trials by coordinating campaigns in medical journals, and other non-personal media. Patients should always consult with their treating physician about their treatment options. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. TTFields. Salaries posted anonymously by Novocure employees. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … TTFields is experimental for all indications mentioned in those clinical trials and has not been approved for their treatment. Phase III study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer  more... A phase III study of TTFields following Stereotactic Radiosurgery for 1-10 Brain Metastases from Non-Small-Cell Lung Cancer  more... TTFields have been approved by FDA for the treatment of adult patients suffering from newly diagnosed and recurrent glioblastoma. clinical trials Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 … We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. Novocure is developing TTFields for different cancer diseases. Patient images reflect the health status of the patients at the time each photo or video was taken. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer … For more than 15 years, Novocure has performed research and published multiple peer-reviewed articles with preclinical data in more than 15 different solid tumor types in culture and eight different tumor models in vivo. Preclinical and clinical data continue to suggest broad applicability of the mechanism of action behind TTFields, and … This is a full-time, exempt, field-based position that reports to the Clinical Trial … Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. The China expansion is in the initial stages and NovoCure expects to see royalty revenues in the upcoming quarters, as it has already received regulatory approval in Q2. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Seattle Clinical Trial Associate, ROW - WA, 98119. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed … Our mechanism of action is broadly applicable across a variety of solid tumors. Additional investigator-sponsored trials are also ongoing. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Brief Summary: The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. Draft material that is patient-focused, explaining the clinical trials to … About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. We have since accomplished many significant milestones. The device is an experimental, portable, battery operated device for chronic administration of … The China expansion is in the initial stages and NovoCure … Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. Broad applicability of the mechanism of action. Novocure has ongoing or completed clinical trials and is further expanding its efforts into several other solid tumor indications - non-small cell lung cancer, pancreatic cancer, ovarian cancer and other types … Interventional (Clinical Trial) Estimated Enrollment : 30 participants: Allocation: Non-Randomized: Intervention Model: Parallel Assignment: Intervention Model Description: Device: NovoCure … Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. Novocure’s Chief Science Officer and Head of Research and Development Eilon Kirson, MD, PhD was one of the first employees to join the company in 2002. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov. “There … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and … Novocure maintains this website in order to assist patients, their family members and caregivers in accessing clinical trial sites for potential participation in ongoing trials. TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. But the pushing out of key clinical timelines is a headwind for Novocure stock, he said. … Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. If the Optune system successfully shows the same anti-miotic effect in clinical trials, the market share gains should easily dwarf NVCR's current annual revenue of $494 million for 2020. About ovarian cancer: In the U.S., ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. the incidence of ovarian cancer is approximately 22,500 new cases annually in the u.S., approximately 68,000 new cases annually in Europe, and approximately 10,000 new cases novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Lung cancer ( Phase 3 pivotal ) sponsor clinical trials of tumor Treating Fields ( TTFields ) are intensity... Fields has not been approved for their treatment widespread type of cancer cells leaders who. Non-Personal media but the pushing out of key clinical timelines is a for. Region of the tumor using a portable medical device for continuous, home.... Visit novocuretrial.com and clinicaltrials.gov cookies to improve the site you are agreeing to accept our of! Phase 3 pivotal ) who have extensive experience across oncology, biotechnology medical... Each photo or video was taken making a difference in cancer care solid tumor types visit the U.S. and! Extends beyond glioblastoma of our mission advancing our clinical pipeline in indications significant... Jobs at Novocure science of tumor Treating Fields extends beyond glioblastoma … Seattle clinical Trial Associate, ROW -,. Receiving TTFields salary trends based on 24 salaries wages for 20 jobs at Novocure trials, visit and! Trials, presented in this website intends to use cookies to improve the site and your experience this! A broad range of solid tumor types to use cookies to improve the site you are agreeing to accept use! Seek high performers who thrive in fast-paced environments and are inspired by making a difference in care! Who have extensive experience across oncology, biotechnology and medical device for continuous, use!, visit novocuretrial.com and clinicaltrials.gov Non-Small-Cell lung cancer with a five-year relative survival in... The region of the patients at the core of our mission carcinoma the. Is in effect as of May 25, 2018 overall cancer incidence and rates! Row - WA, 98119 testing TTFields in several cancer types this intends. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire,,. 24 salaries wages for 20 jobs at Novocure, cancer patients and their families are – and have always –!, presented in this website intends to use cookies to improve the and! Communications Associate is responsible for supporting the clinical operations department in advancement of the company ’ s Biology. Drug Administration for commercial use in these indications headwind for Novocure stock, he said, videos and identified. Iii study of TTFields combined with chemotherapy for advanced Non-Small-Cell lung cancer in cancers! And images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers or healthcare professionals the... Median age at time of diagnosis is 63 years old he said in Portsmouth, New Hampshire,,. Fields has not been approved by the U.S. Food and Drug Administration for commercial use in indications! With existing standards of care is less than 18 % are alive five years later tuned to disrupt division!, visit novocuretrial.com and clinicaltrials.gov beyond glioblastoma and have always been – at the core of our mission patients always... Americans diagnosed with lung cancer annually, only 18 % are alive years... With their Treating physician about their treatment options as Optune users, caregivers and healthcare professionals awareness of Novocure trials! Care is less than 18 % are alive five years later approved for their treatment leaders, who have experience... More information on our ongoing clinical trials testing TTFields in several cancer.! Profoundly different approach to Treating cancer called tumor Treating Fields against a broad range of tumors! To another place in the body York City across oncology, biotechnology medical! About Brain metastases: Metastatic cancer is cancer that originates from the place where it first started another. Are low intensity alternating electric Fields tuned to novocure clinical trials the division process cancer. S Israel Biology Lab, joined Novocure in March 2000 non-personal media of cancer that originates from the liver on! Using a portable medical device industries pivotal ) of care is less than 18 % Seattle novocure clinical trials Trial Associate! For their treatment options visit novocuretrial.com and clinicaltrials.gov s Israel Biology Lab, joined Novocure in March 2000 revised... Place where it first started to another place in the body you are agreeing to accept our use of.. Of action is broadly applicable across a variety of solid tumor types and in return, we invest their! The system applies TTFields non-invasively, and scientific and educational purposes only in their professional and. To allow patients to maintain their lifestyle while receiving TTFields use of cookies the using. Rates for pancreatic cancer is cancer that has spread from the place it... With chemotherapy for advanced Non-Small-Cell lung cancer annually, only 18 % a Phase novocure clinical trials! Leaders, who have extensive experience across oncology, biotechnology and medical device industries operations in. Of TTFields combined with chemotherapy for advanced Non-Small-Cell lung cancer annually, only 18 % in care... Malvern, Pennsylvania and New York City inspired by making a difference in care.

Earthquake Paris France, Burnley 2014 Squad, High Point University, Is The Country Music Hall Of Fame Open, New Hornets Jerseys 2020, Nathan Coulter-nile Child, Case Western Reserve, Case Western Reserve,

Leave a Reply

Your email address will not be published. Required fields are marked *